Detailed Information on Publication Record
2018
Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study
GAYAT, Etienne, Mattia ARRIGO, Simona LITTNEROVÁ, Naoki SATO, Jiří PAŘENICA et. al.Basic information
Original name
Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study
Authors
GAYAT, Etienne (250 France, guarantor), Mattia ARRIGO (756 Switzerland), Simona LITTNEROVÁ (203 Czech Republic, belonging to the institution), Naoki SATO (392 Japan), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Shiro ISHIHARA (392 Japan), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Christian MULLER (756 Switzerland), Veli-Pekka HARJOLA (246 Finland), Johan LASSUS (246 Finland), Oscar MIRO (724 Spain), Aldo P. MAGGIONI (380 Italy), Khalid F. ALHABIB (682 Saudi Arabia), Dong-Ju CHOI (410 Republic of Korea), Jin Joo PARK (410 Republic of Korea), Yuhui ZHANG (156 China), Jian ZHANG (156 China), James L., Jr. JANUZZI (840 United States of America), Katsuya KAJIMOTO (392 Japan), Alain COHEN-SOLAL (250 France) and Alexandre MEBAZAA (250 France)
Edition
European Journal of heart Failure, Hoboken, Wiley, 2018, 1388-9842
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 12.129
RIV identification code
RIV/00216224:14110/18:00102127
Organization unit
Faculty of Medicine
UT WoS
000429044500022
Keywords in English
Acute heart failure; Prognosis; Oral therapy
Tags
International impact, Reviewed
Změněno: 10/2/2019 13:24, Soňa Böhmová
Abstract
V originále
Aims Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome. However, concerns have been raised because early administration of HFOTs may worsen patient's condition. We hypothesized that HFOTs at hospital discharge might be associated with better post-discharge survival.& para;& para;Methods and results The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and secondary and results outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with univariate and covariate-adjusted Cox proportional hazards regression models for the whole population and after propensity-score matching. HFOTs at discharge were consistently associated with no excess mortality in the unadjusted and adjusted analyses of the whole and matched cohorts. In the matched cohort, BB and RASi at discharge were associated with lower 90-day mortality risks compared to the respective untreated groups [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.46-0.69; and HR 0.53, 95% CI 0.42-0.66, respectively]. The favourable associations of BB and RASi at discharge with 90-day mortality were present in many subgroups including patients with reduced or preserved left ventricular ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was associated with an even lower risk of death than RASi or BB alone.& para;& para;Conclusions Administration of HFOTs at hospital discharge is associated with better survival of AHF patients.
Links
| MUNI/A/1365/2015, interní kód MU |
|